Gene Therapy for Heart Failure: New Perspectives

Current Heart Failure Reports

Volumn 15, Issue 6, 2018, Pages 340-349

  Gabisonia, Khatia ^a   Recchia, Fabio A ^a,b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AAV; Duchenne cardiomyopathy; Gene therapy; Heart failure; Hippo pathway; miRNA

Indexed keywords

MESSENGER RNA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; VASCULOTROPIN B; VIRUS VECTOR; MICRORNA;

CELL PROLIFERATION ASSAY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR-CAS9 SYSTEM; DUCHENNE CARDIOMYOPATHY; DUCHENNE MUSCULAR DYSTROPHY; GENE EDITING; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEART FAILURE; HEART INJURY; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; RNA SPLICING; SURVIVAL ANALYSIS; ANIMAL; GENETICS; PROCEDURES;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; GENETIC THERAPY; HEART FAILURE; HUMANS; MICRORNAS;

EID: 85053765334     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-018-0410-z     Document Type: Review

References (115)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. J Card Fail. 2017;23(8):628–51. 10.1016/j.cardfail.2017.04.014
2. Nguyen E, Weeda ER, White CM. A review of new pharmacologic treatments for patients with chronic heart failure with reduced ejection fraction. J Clin Pharmacol. 2016;56(8):936–47. 10.1002/jcph.677
3. Anderson WF. Human gene therapy. Science. 1992;256(5058):808–13. 10.1126/science.256.5058.808
4. Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation. 1990;82(6):2217–21. 10.1161/01.CIR.82.6.2217
5. Zacchigna S, Giacca M. Extra- and intracellular factors regulating cardiomyocyte proliferation in postnatal life. Cardiovasc Res. 2014;102(2):312–20. 10.1093/cvr/cvu057
6. Greenberg B. Gene therapy for heart failure. J Cardiol. 2015;66(3):195–200. 10.1016/j.jjcc.2015.02.006
7. Hulot J-S, Ishikawa K, Hajjar RJ. Gene therapy for the treatment of heart failure: promise postponed. Eur Heart J. 2016;37(21):1651–8. 10.1093/eurheartj/ehw019
8. Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res. 2015;108(1):4–20. 10.1093/cvr/cvv205
9. Stammers AN, Susser SE, Hamm NC, Hlynsky MW, Kimber DE, Kehler DS, et al. The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA). Can J Physiol Pharmacol. 2015;93(10):843–54. 10.1139/cjpp-2014-0463
10. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004;10(3):248–54. 10.1038/nm1000
11. Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med. 2008;5(9):554–65. 10.1038/ncpcardio1301
12. Pathak A, del Monte F, Zhao W, Schultz JE, Lorenz JN, Bodi I, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005;96(7):756–66. 10.1161/01.RES.0000161256.85833.fa
13. Watanabe S, Ishikawa K, Fish K, Oh JG, Motloch LJ, Kohlbrenner E, et al. Protein phosphatase Inhibitor-1 gene therapy in a swine model of nonischemic heart failure. J Am Coll Cardiol. 2017;70(14):1744–56. 10.1016/j.jacc.2017.08.013
14. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97(2):793–8
15. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100(23):2308–11
16. Lyon AR, Bannister ML, Collins T, Pearce E, Sepehripour AH, Dubb SS, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol. 2011;4(3):362–72. 10.1161/CIRCEP.110.961615
17. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51(11):1112–9. 10.1016/j.jacc.2007.12.014
18. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124(3):304–13. 10.1161/CIRCULATIONAHA.111.022889
19. Greenberg B, Yaroshinsky A, Zsebo KM, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail. 2014;2(1):84–92. 10.1016/j.jchf.2013.09.008
20. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016;387(10024):1178–86. 10.1016/S0140-6736(16)00082-9
21. Yang L, Jiang J, Drouin LM, Agbandje-Mckenna M, Chen C, Qiao C, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A. 2009;106(10):3946–51. 10.1073/pnas.0813207106
22. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol. 2010;28(1):79–82. 10.1038/nbt.1599
23. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(9):872–6. 10.1038/sj.embor.7400221
24. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51(8):759–64. 10.1111/jpc.12868
25. Manning J, O’Malley D. What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease? J Muscle Res Cell Motil. 2015;36(2):155–67. 10.1007/s10974-015-9406-4
26. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177–89. 10.1016/S1474-4422(09)70272-8
27. Yue Y, Binalsheikh IM, Leach SB, Domeier TL, Duan D. Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs. 2016;4(2):169–83. 10.1517/21678707.2016.1124039
28. Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther. 2006;13(2):241–9. 10.1016/j.ymthe.2005.11.001
29. Abdul-Razak H, Malerba A, Dickson G. Advances in gene therapy for muscular dystrophies. F1000Res. 2016;5. 10.12688/f1000research.8735.1
30. Foster H, Popplewell L, Dickson G. Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum Gene Ther. 2012;23(7):676–87. 10.1089/hum.2012.099
31. Duan D. Duchenne muscular dystrophy gene therapy: lost in translation? Res Rep Biol. 2011;2011(2):31–42. 10.2147/RRB.S13463
32. Forbes SC, Bish LT, Ye F, Spinazzola J, Baligand C, Plant D, et al. Gene transfer of arginine kinase to skeletal muscle using adeno-associated virus. Gene Ther. 2014;21(4):387–92. 10.1038/gt.2014.9
33. Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012;20(2):443–55. 10.1038/mt.2011.237
34. Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther. 2017;25(5):1125–31. 10.1016/j.ymthe.2017.02.019
35. Toromanoff A, Adjali O, Larcher T, Hill M, Guigand L, Chenuaud P, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther. 2010;18(1):151–60. 10.1038/mt.2009.251
36. Rodino-Klapac LR, Montgomery CL, Bremer WG, Shontz KM, Malik V, Davis N, et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther. 2010;18(1):109–17. 10.1038/mt.2009.254
37. Kodippili K, Hakim CH, Pan X, Yang HT, Yue Y, Zhang Y, et al. Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther. 2018;29(3):299–311. 10.1089/hum.2017.095
38. Duan D. Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev. 2015;26(1):57–69. 10.1089/humc.2015.006
39. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther. 2012;20(8):1501–7. 10.1038/mt.2012.111
40. Systemic gene delivery clinical trial for Duchenne muscular dystrophy https://clinicaltrials.gov/ct2/show/NCT03375164?cond=%22Muscular+Dystrophy%2C+Duchenne%22&lupd_s=11%2F13%2F2015&lupd_d=1000
41. A study to evaluate the safety and tolerability of PF-06939926 gene therapy in Duchenne muscular dystrophy https://clinicaltrials.gov/ct2/show/NCT03362502?cond=%22Muscular+Dystrophy%2C+Duchenne%22&lupd_s=11%2F13%2F2015&lupd_d=1000
42. Gene transfer clinical trial to deliver rAAVrh74.MCK.GALGT2 for Duchenne muscular dystrophy https://clinicaltrials.gov/ct2/show/NCT03333590?cond=%22Muscular+Dystrophy%2C+Duchenne%22&lupd_s=11%2F13%2F2015&lupd_d=1000
43. Nance ME, Duan D. Perspective on adeno-associated virus capsid modification for Duchenne muscular dystrophy gene therapy. Hum Gene Ther. 2015;26(12):786–800. 10.1089/hum.2015.107
44. Ghosh A, Duan D. Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev. 2007;24:165–77
45. Lai Y, Yue Y, Liu M, Ghosh A, Engelhardt JF, Chamberlain JS, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol. 2005;23(11):1435–9. 10.1038/nbt1153
46. Koo T, Popplewell L, Athanasopoulos T, Dickson G. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum Gene Ther. 2014;25(2):98–108. 10.1089/hum.2013.164
47. Chapdelaine P, Pichavant C, Rousseau J, Paques F, Tremblay JP. Meganucleases can restore the reading frame of a mutated dystrophin. Gene Ther. 2010;17(7):846–58. 10.1038/gt.2010.26
48. Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther. 2013;21(9):1718–26. 10.1038/mt.2013.111
49. Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, et al. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther. 2015;23(3):523–32. 10.1038/mt.2014.234
50. Popplewell L, Koo T, Leclerc X, Duclert A, Mamchaoui K, Gouble A, et al. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. Hum Gene Ther. 2013;24(7):692–701. 10.1089/hum.2013.081
51. Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C. Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front Genet. 2018;9:114. 10.3389/fgene.2018.00114
52. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351(6271):403–7. 10.1126/science.aad5143
53. Wang J-Z, Wu P, Shi Z-M, Xu Y-L, Liu Z-J. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD. Brain and Development. 2017;39(7):547–56. 10.1016/j.braindev.2017.03.024
54. Zhu P, Wu F, Mosenson J, Zhang H, He T-C, Wu W-S. CRISPR/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy. Mol Ther Nucleic Acids. 2017;7:31–41. 10.1016/j.omtn.2017.02.007
55. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637–47. 10.1002/ana.23982
56. Nakamura A. Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy. J Hum Genet. 2017;62(10):871–6. 10.1038/jhg.2017.57
57. Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, Silva O, et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med. 2012;4(164):164ra160. 10.1126/scitranslmed.3005054
58. McElhanon KE, Bhattacharya S. Altered membrane integrity in the progression of muscle diseases. Life Sci. 2018;192:166–72. 10.1016/j.lfs.2017.11.035
59. Le Hir M, Goyenvalle A, Peccate C, et al. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Mol Ther. 2013;21(8):1551–8. 10.1038/mt.2013.121
60. Stedman HH, Byrne BJ. Signs of progress in gene therapy for muscular dystrophy also warrant caution. Mol Ther. 2012;20(2):249–51. 10.1038/mt.2011.307
61. Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther. 2010;18(8):1501–8. 10.1038/mt.2010.94
62. Zaccolo M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol. 2009;158(1):50–60. 10.1111/j.1476-5381.2009.00185.x
63. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lai YY, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004;110(3):330–6. 10.1161/01.CIR.0000136033.21777.4D
64. Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, Ander A, et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation. 2002;105(16):1989–94
65. Timofeyev V, He Y, Tuteja D, Zhang Q, Roth DM, Hammond HK, et al. Cardiac-directed expression of adenylyl cyclase reverses electrical remodeling in cardiomyopathy. J Mol Cell Cardiol. 2006;41(1):170–81. 10.1016/j.yjmcc.2006.04.008
66. Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, et al. Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 2016;1(2):163–71. 10.1001/jamacardio.2016.0008
67. Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation. 2006;114(12):1258–68. 10.1161/CIRCULATIONAHA.106.622415
68. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ, et al. Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol. 2007;27(12):4365–73. 10.1128/MCB.02045-06
69. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med. 2011;3(92):92ra64. 10.1126/scitranslmed.3002097
70. Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, et al. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther. 2014;21(2):131–8. 10.1038/gt.2013.63
71. uniQure N.V. Annual report 2017. http://www.uniqure.com/uniQure%20Annual%20Accounts%202017.pdf
72. Sen A, Ren S, Lerchenmuller C, et al. MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. PLoS One. 2013;8(11):e78684. 10.1371/journal.pone.0078684
73. Bry M, Kivelä R, Leppänen VM, Alitalo K. Vascular endothelial growth factor-B in physiology and disease. Physiol Rev. 2014;94:779–94
74. Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest. 2008;118:913–23
75. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182–9
76. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131–41
77. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Investig. 1999;29:380–6
78. Khatiwala JR, Everly MJ. An update on cardiac transplantation in the United States based on an analysis of the UNOS registry. Clin Transpl. 2015;31:27–34
79. Zentilin L, Puligadda U, Lionetti V, Zacchigna S, Collesi C, Pattarini L, et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J. 2010;24:1467–78
80. Pepe M, Mamdani M, Zentilin L, Csiszar A, Qanud K, Zacchigna S, et al. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res. 2010;106:1893–903
81. Woitek F, Zentilin L, Hoffman NE, Powers JC, Ottiger I, Parikh S, et al. Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated cardiomyopathy. J Am Coll Cardiol. 2015;66:139–53
82. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362(9385):697–703. 10.1016/S0140-6736(03)14232-8
83. Penn MS, Pastore J, Miller T, Aras R. SDF-1 in myocardial repair. Gene Ther. 2012;19(6):583–7. 10.1038/gt.2012.32
84. Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore J, et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res. 2013;112(5):816–25. 10.1161/CIRCRESAHA.111.300440
85. Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized phase II trial. Eur Heart J. 2015;36(33):2228–38. 10.1093/eurheartj/ehv254
86. Durrani S, Konoplyannikov M, Ashraf M, Haider KH. Skeletal myoblasts for cardiac repair. Regen Med. 2010;5(6):919–32. 10.2217/rme.10.65
87. Psaltis PJ, Schwarz N, Toledo-Flores D, Nicholls SJ. Cellular therapy for heart failure. Curr Cardiol Rev. 2016;12(3):195–215. 10.2174/1573403X12666160606121858
88. Ptaszek LM, Mansour M, Ruskin JN, Chien KR. Towards regenerative therapy for cardiac disease. Lancet. 2012;379(9819):933–42. 10.1016/S0140-6736(12)60075-0
89. Zhang Y, Mignone J, MacLellan WR. Cardiac regeneration and stem cells. Physiol Rev. 2015;95(4):1189–204. 10.1152/physrev.00021.2014
90. Steinhoff G, Nesteruk J, Wolfien M, Große J, Ruch U, Vasudevan P, et al. Stem cells and heart disease—brake or accelerator? Adv Drug Deliv Rev. 2017;120:2–24. 10.1016/j.addr.2017.10.007
91. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98–102. 10.1126/science.1164680
92. Chaudhry HW, Dashoush NH, Tang H, Zhang L, Wang X, Wu EX, et al. Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J Biol Chem. 2004;279(34):35858–66. 10.1074/jbc.M404975200
93. Woo YJ, Panlilio CM, Cheng RK, et al. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation. 2006;114(1 Suppl):I206–13. 10.1161/CIRCULATIONAHA.105.000455
94. Liao HS, Kang PM, Nagashima H, Yamasaki N, Usheva A, Ding B, et al. Cardiac-specific overexpression of cyclin-dependent kinase 2 increases smaller mononuclear cardiomyocytes. Circ Res. 2001;88(4):443–50
95. Pasumarthi KBS, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res. 2005;96(1):110–8. 10.1161/01.RES.0000152326.91223.4F
96. Hassink RJ, Pasumarthi KB, Nakajima H, Rubart M, Soonpaa MH, de la Riviere AB, et al. Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovasc Res. 2008;78(1):18–25. 10.1093/cvr/cvm101
97. Mahmoud AI, Kocabas F, Muralidhar SA, Kimura W, Koura AS, Thet S, et al. Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature. 2013;497(7448):249–53. 10.1038/nature12054
98. Xiang F-L, Guo M, Yutzey KE. Overexpression of Tbx20 in adult cardiomyocytes promotes proliferation and improves cardiac function after myocardial infarction. Circulation. 2016;133(11):1081–92. 10.1161/CIRCULATIONAHA.115.019357
99. Eulalio A, Mano M, Dal Ferro M, et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492(7429):376–81. 10.1038/nature11739
100. Tian Y, Liu Y, Wang T, Zhou N, Kong J, Chen L, et al. A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. Sci Transl Med. 2015;7(279):279ra38. 10.1126/scitranslmed.3010841
101. Meng Z, Moroishi T, Guan K-L. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30(1):1–17. 10.1101/gad.274027.115
102. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138(1):9–22. 10.1242/dev.045500
103. Leach JP, Heallen T, Zhang M, Rahmani M, Morikawa Y, Hill MC, et al. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature. 2017;550(7675):260–4. 10.1038/nature24045
104. Morikawa Y, Zhang M, Heallen T, Leach J, Tao G, Xiao Y, et al. Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice. Sci Signal. 2015;8(375):ra41. 10.1126/scisignal.2005781
105. Tao G, Kahr PC, Morikawa Y, Zhang M, Rahmani M, Heallen TR, et al. Pitx2 promotes heart repair by activating the antioxidant response after cardiac injury. Nature. 2016;534(7605):119–23. 10.1038/nature17959
106. Heallen T, Morikawa Y, Leach J, Tao G, Willerson JT, Johnson RL, et al. Hippo signaling impedes adult heart regeneration. Development. 2013;140(23):4683–90. 10.1242/dev.102798
107. Chen J, Huang Z-P, Seok HY, Ding J, Kataoka M, Zhang Z, et al. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res. 2013;112(12):1557–66. 10.1161/CIRCRESAHA.112.300658
108. Zhang Y, Matsushita N, Eigler T, Marban E. Targeted microRNA interference promotes postnatal cardiac cell cycle re-entry. J Regen Med. 2013;2:2. 10.4172/2325-9620.1000108
109. Porrello ER, Johnson BA, Aurora AB, Simpson E, Nam YJ, Matkovich SJ, et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res. 2011;109(6):670–9. 10.1161/CIRCRESAHA.111.248880
110. Castellan RFP, Meloni M. Mechanisms and therapeutic targets of cardiac regeneration: closing the age gap. Front Cardiovasc Med. 2018;5:7. 10.3389/fcvm.2018.00007
111. Lin Z, Pu WT. Releasing YAP from an α-catenin trap increases cardiomyocyte proliferation. Circ Res. 2015;116(1):9–11. 10.1161/CIRCRESAHA.114.305496
112. Huynh K. Basic research: inhibition of Hippo pathway signalling reverses systolic heart failure. Nat Rev Cardiol. 2017;14(12):697. 10.1038/nrcardio.2017.166
113. Cahill TJ, Choudhury RP, Riley PR. Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics. Nat Rev Drug Discov. 2017;16(10):699–717. 10.1038/nrd.2017.106
114. Hill MC, Martin JF. Heart muscle regeneration: the wonder of a cardio-cocktail. Cell Res. 2018;28(5):503–4. 10.1038/s41422-018-0035-5
115. Gabisonia K, Prosdocimo G, Aquaro GD, et al. Intramyocardial delivery of miR-199a reduces scar size and preserves contractile function in infarcted pig hearts. 2016 AHA late-breaking basic science abstracts. Circ Res. 2016;119:e160–71. 10.1161/RES.0000000000000126